ST人福：HW221043片获药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of HW221043 tablets, which are intended for the treatment of advanced solid tumors and represent a new molecular entity with no similar drugs approved in the market to date [1] Group 1 - The full subsidiary of the company, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., has been granted the clinical trial approval notice for HW221043 tablets [1] - HW221043 tablets are developed independently by the company and are aimed at treating advanced solid tumors [1] - The total research and development investment for HW221043 tablets has reached approximately 24 million RMB [1]